Middle East and North African leaders seek solutions to diabetes threat

Novo NordiskThe Middle East and Northern Africa (MENA) region is facing one of the greatest healthcare challenges of our time: the diabetes pandemic. It is estimated that 26.6 million people in the region have diabetes and this number is set to double to 51.7 million by 2030.

To help find solutions to this challenge, Novo Nordisk is sponsoring a Diabetes Leadership Forum on 12-13 December in Dubai. At the Forum, a group of over 600 regional and international experts and decision-makers from 22 countries and territories in the MENA region will participate. The attending countries are Afghanistan, Algeria, Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Pakistan, Palestinian National Authority, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, UAE and Yemen.

This high-level event will feature keynote addresses by President Bill Clinton, founder of The William J Clinton Foundation, and His Royal Highness Crown Prince Frederik of Denmark.

"Our hope with this event is to find solutions to the diabetes challenge in the MENA region. We know we can improve on diabetes prevention, early detection and quality of care. The meeting is about sharing the responsibility of fighting diabetes and committing to taking action on a national and regional level," says Lars Rebien Sørensen, president and CEO of Novo Nordisk.

The aim of the Forum is that all participating nations will adopt the Dubai Diabetes Declaration, featuring country-specific action plans designed to turn the trend in diabetes, which is imposing overwhelming demands on the region's healthcare systems and financial burdens on its governments. Ultimately, the hope is to contribute to changing behaviours in the entire MENA region when dealing with diabetes.

As part of its Changing Diabetes® Leadership Forum initiative, Novo Nordisk is organising and sponsoring the MENA Diabetes Leadership Forum, opening in Dubai, UAE on 12 December. Held under the high patronage of His Highness Sheikh Hamdan bin Rashid Al Maktoum, Deputy Ruler of Dubai and Minister of Finance of the UAE, the Forum is hosted by the UAE Ministry of Health together with the executive board of the Health Ministers’ Council for Gulf Cooperation Council States (GCC), the World Diabetes Foundation and the World Bank Group (MENA region).

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Blocking enzyme could hold the key to preventing, …

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

GSK to acquire clinical-stage biopharmaceutical co…

GSK plc (LSE/NYSE: GSK) announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...